The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …

Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …

Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with
a DNA hypomethylating agent or low dose cytarabine, results in high rates of initial …

The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term
survival rate less than 50%. However, the current paradigms of treatment are changing …

Venetoclax (VEN) is a selective BCL-2 inhibitor that has been shown to be effective when
used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for …

Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA‐approved for
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …

Despite the success of the combination of venetoclax with the hypomethylating agents
(HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients …

PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in
acute myeloid leukemia (AML), with promising response rates in combination with …